Loading...
Market
What will be heparin's market share in snakebite treatment by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Market analysis reports from firms like Grand View Research or MarketWatch
Story
Common Blood Thinner Heparin Found to Neutralize Cobra Venom and Flesh-Eating Snake Bites
Jul 17, 2024, 08:23 PM
A global study suggests that the common blood thinner heparin could be repurposed as an antidote to cobra venom. Researchers from Australia, Canada, Costa Rica, and the UK, including Sydney scientists, have discovered that heparin can neutralize the venom, potentially revolutionizing the treatment of cobra bites and flesh-eating snake bites. This development could drastically reduce the terrible injuries caused by cobra bites and improve survival rates, preventing thousands of deaths. The study indicates that heparin may also prevent snakebite victims from losing limbs, offering a cheap and effective solution to a significant medical issue.
View original story
Similar markets
United States • 25%
European Union • 25%
Asia • 25%
Other • 25%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
American Medical Association (AMA) • 25%
World Health Organization (WHO) • 25%
Centers for Disease Control and Prevention (CDC) • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%